{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:05:41Z","timestamp":1792076741860,"version":"4.4.0"},"reference-count":25,"publisher":"National Academy of Sciences","issue":"19","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2019,5,7]]},"abstract":"<jats:p>\n                    Visceral leishmaniasis (VL), caused by the protozoan parasites\n                    <jats:italic>Leishmania donovani<\/jats:italic>\n                    and\n                    <jats:italic>Leishmania infantum<\/jats:italic>\n                    , is one of the major parasitic diseases worldwide. There is an urgent need for new drugs to treat VL, because current therapies are unfit for purpose in a resource-poor setting. Here, we describe the development of a preclinical drug candidate, GSK3494245\/DDD01305143\/compound 8, with potential to treat this neglected tropical disease. The compound series was discovered by repurposing hits from a screen against the related parasite\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    . Subsequent optimization of the chemical series resulted in the development of a potent cidal compound with activity against a range of clinically relevant\n                    <jats:italic>L. donovani<\/jats:italic>\n                    and\n                    <jats:italic>L. infantum<\/jats:italic>\n                    isolates. Compound 8 demonstrates promising pharmacokinetic properties and impressive in vivo efficacy in our mouse model of infection comparable with those of the current oral antileishmanial miltefosine. Detailed mode of action studies confirm that this compound acts principally by inhibition of the chymotrypsin-like activity catalyzed by the \u03b25 subunit of the\n                    <jats:italic>L. donovani<\/jats:italic>\n                    proteasome. High-resolution cryo-EM structures of apo and compound 8-bound\n                    <jats:italic>Leishmania tarentolae<\/jats:italic>\n                    20S proteasome reveal a previously undiscovered inhibitor site that lies between the \u03b24 and \u03b25 proteasome subunits. This induced pocket exploits \u03b24 residues that are divergent between humans and kinetoplastid parasites and is consistent with all of our experimental and mutagenesis data. As a result of these comprehensive studies and due to a favorable developability and safety profile, compound 8 is being advanced toward human clinical trials.\n                  <\/jats:p>","DOI":"10.1073\/pnas.1820175116","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T20:28:13Z","timestamp":1554755293000},"page":"9318-9323","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":175,"title":["Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition"],"prefix":"10.1073","volume":"116","author":[{"given":"Susan","family":"Wyllie","sequence":"first","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Brand","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3171-3519","authenticated-orcid":false,"given":"Manu","family":"De Rycker","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-wa","family":"Chung","sequence":"additional","affiliation":[{"name":"Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imanol","family":"Pena","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Bingham","sequence":"additional","affiliation":[{"name":"Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Bueren-Calabuig","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Cantizani","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cebrian","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Craggs","sequence":"additional","affiliation":[{"name":"Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panchali","family":"Goswami","sequence":"additional","affiliation":[{"name":"Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hobrath","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Howe","sequence":"additional","affiliation":[{"name":"David Jack Centre for R&amp;D, GlaxoSmithKline, Ware SG12 0DP, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jeacock","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Jung","family":"Ko","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Korczynska","sequence":"additional","affiliation":[{"name":"Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"MacLean","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Manthri","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria S.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Mata-Cantero","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Moniz","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"N\u00fchs","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Osuna-Cabello","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Pinto","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Riley","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Robinson","sequence":"additional","affiliation":[{"name":"David Jack Centre for R&amp;D, GlaxoSmithKline, Ware SG12 0DP, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Rowland","sequence":"additional","affiliation":[{"name":"Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R. C.","family":"Simeons","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shishikura","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Spinks","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laste","family":"Stojanovski","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Thomas","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Thompson","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Viayna Gaza","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Wall","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Zuccotto","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5173-9284","authenticated-orcid":false,"given":"David","family":"Horn","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A. J.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-0329","authenticated-orcid":false,"given":"Alan H.","family":"Fairlamb","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Fiandor","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Martin","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Gray","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Miles","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5238-1314","authenticated-orcid":false,"given":"Ian H.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin D.","family":"Read","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-0021","authenticated-orcid":false,"given":"Maria","family":"Marco","sequence":"additional","affiliation":[{"name":"Global Health R&amp;D, GlaxoSmithKline, Tres Cantos, 28760, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Wyatt","sequence":"additional","affiliation":[{"name":"Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2019,4,8]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza S","year":"2018","unstructured":"S Burza, SL Croft, M Boelaert, Leishmaniasis. Lancet 392, 951\u2013970 (2018).","journal-title":"Lancet"},{"key":"e_1_3_4_2_2","unstructured":"; Control of Neglected Tropical Diseases (NTD) World Health Organization Status of endemicity of visceral leishmaniasis worldwide. Available at www.who.int\/leishmaniasis\/burden\/Status_of_endemicity_of_VL_worldwide_2015_with_imported_cases.pdf?ua=1. Accessed March 14 2019. (2015)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CLEP.S44267","article-title":"Epidemiology of visceral leishmaniasis","volume":"6","author":"Ready PD","year":"2014","unstructured":"PD Ready, Epidemiology of visceral leishmaniasis. Clin Epidemiol 6, 147\u2013154 (2014).","journal-title":"Clin Epidemiol"},{"key":"e_1_3_4_4_2","first-page":"193","article-title":"Visceral leishmaniasis and HIV coinfection: Current perspectives","volume":"10","author":"Lindoso JAL","year":"2018","unstructured":"JAL Lindoso, CHV Moreira, MA Cunha, IT Queiroz, Visceral leishmaniasis and HIV coinfection: Current perspectives. HIV AIDS (Auckl) 10, 193\u2013201 (2018).","journal-title":"HIV AIDS (Auckl)"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal S","year":"2013","unstructured":"S Rijal, , Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance. Clin Infect Dis 56, 1530\u20131538 (2013).","journal-title":"Clin Infect Dis"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure","volume":"210","author":"Dorlo TP","year":"2014","unstructured":"TP Dorlo, , Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure. J Infect Dis 210, 146\u2013153 (2014).","journal-title":"J Infect Dis"},{"key":"e_1_3_4_7_2","doi-asserted-by":"crossref","first-page":"e2613","DOI":"10.1371\/journal.pntd.0002613","article-title":"Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: A randomised trial","volume":"8","author":"Khalil EA","year":"2014","unstructured":"EA Khalil, , Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: A randomised trial. PLoS Negl Trop Dis 8, e2613 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_4_8_2","doi-asserted-by":"crossref","first-page":"e0004880","DOI":"10.1371\/journal.pntd.0004880","article-title":"Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial","volume":"10","author":"Wasunna M","year":"2016","unstructured":"M Wasunna, , Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: Phase II randomized trial. PLoS Negl Trop Dis 10, e0004880 (2016).","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_4_9_2","volume-title":"Drug Discovery for Leishmaniasis","author":"Alvar J","year":"2018","unstructured":"J Alvar, B Arana, Leishmaniasis, impact and therapeutic needs. Drug Discovery for Leishmaniasis, eds L Rivas, C Gil (The Royal Society of Chemistry, London, 2018)."},{"key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.1021\/jm400362b","article-title":"Drug discovery for neglected diseases: Molecular target-based and phenotypic approaches","volume":"56","author":"Gilbert IH","year":"2013","unstructured":"IH Gilbert, Drug discovery for neglected diseases: Molecular target-based and phenotypic approaches. J Med Chem 56, 7719\u20137726 (2013).","journal-title":"J Med Chem"},{"key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S003118201300142X","article-title":"Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections","volume":"141","author":"Don R","year":"2014","unstructured":"R Don, JR Ioset, Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections. Parasitology 141, 140\u2013146 (2014).","journal-title":"Parasitology"},{"key":"e_1_3_4_12_2","volume-title":"Drug Discovery for Leishmaniasis","author":"Mart\u00edn J","year":"2018","unstructured":"J Mart\u00edn, J Cantizani, I Pe\u00f1a, The pursuit of novel anti-leishmanial agents by high-throughput screening (HTS) of chemical libraries. Drug Discovery for Leishmaniasis, eds L Rivas, C Gil (The Royal Society of Chemistry, London, 2018)."},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1128\/AAC.02398-12","article-title":"Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay","volume":"57","author":"De Rycker M","year":"2013","unstructured":"M De Rycker, , Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob Agents Chemother 57, 2913\u20132922 (2013).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ddtec.2004.10.009","article-title":"Scaffold hopping","volume":"1","author":"B\u00f6hm H-J","year":"2004","unstructured":"H-J B\u00f6hm, A Flohr, M Stahl, Scaffold hopping. Drug Discov Today Technol 1, 217\u2013224 (2004).","journal-title":"Drug Discov Today Technol"},{"key":"e_1_3_4_15_2","unstructured":"; Drugs for Neglected Diseases initiative DNDi Target product profile for Visceral Leishmaniasis. Available at https:\/\/www.dndi.org\/diseases-projects\/leishmaniasis\/tpp-vl\/. Accessed March 14 2019. (2018)."},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","first-page":"e0004094","DOI":"10.1371\/journal.pntd.0004094","article-title":"Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of Leishmanicidal intracellular activity","volume":"9","author":"N\u00fchs A","year":"2015","unstructured":"A N\u00fchs, , Development and validation of a novel Leishmania donovani screening cascade for high-throughput screening using a novel axenic assay with high predictivity of Leishmanicidal intracellular activity. PLoS Negl Trop Dis 9, e0004094 (2015).","journal-title":"PLoS Negl Trop Dis"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie S","year":"2018","unstructured":"S Wyllie, , Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature 560, 192\u2013197 (2018).","journal-title":"Nature"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1128\/AAC.45.6.1872-1875.2001","article-title":"Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice","volume":"45","author":"Escobar P","year":"2001","unstructured":"P Escobar, V Yardley, SL Croft, Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45, 1872\u20131875 (2001).","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10771","article-title":"High-throughput decoding of antitrypanosomal drug efficacy and resistance","volume":"482","author":"Alsford S","year":"2012","unstructured":"S Alsford, , High-throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482, 232\u2013236 (2012).","journal-title":"Nature"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare S","year":"2016","unstructured":"S Khare, , Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. Nature 537, 229\u2013233 (2016).","journal-title":"Nature"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1021\/mp2004143","article-title":"Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib","volume":"9","author":"Berkers CR","year":"2012","unstructured":"CR Berkers, , Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib. Mol Pharm 9, 1126\u20131135 (2012).","journal-title":"Mol Pharm"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/onc.2009.343","article-title":"Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells","volume":"29","author":"Zhu K","year":"2010","unstructured":"K Zhu, Jr K Dunner, DJ McConkey, Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene 29, 451\u2013462 (2010).","journal-title":"Oncogene"},{"key":"e_1_3_4_23_2","first-page":"1144","article-title":"Mechanism of G2\/M cell cycle arrest before apoptosis in leukemia cell line HL-60 induced by proteasome inhibitor MG132","volume":"23","author":"Sun GJ","year":"2004","unstructured":"GJ Sun, , Mechanism of G2\/M cell cycle arrest before apoptosis in leukemia cell line HL-60 induced by proteasome inhibitor MG132. Chin J Cancer 23, 1144\u20131148 (2004).","journal-title":"Chin J Cancer"},{"key":"e_1_3_4_24_2","first-page":"1145","article-title":"Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines","volume":"9","author":"Ling YH","year":"2003","unstructured":"YH Ling, , Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9, 1145\u20131154 (2003).","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.aaf8993","article-title":"The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design","volume":"353","author":"Schrader J","year":"2016","unstructured":"J Schrader, , The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science 353, 594\u2013598 (2016).","journal-title":"Science"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.1820175116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T15:17:01Z","timestamp":1654615021000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.1820175116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,8]]},"references-count":25,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2019,5,7]]}},"alternative-id":["10.1073\/pnas.1820175116"],"URL":"https:\/\/doi.org\/10.1073\/pnas.1820175116","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,8]]},"assertion":[{"value":"2019-04-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}